Table 1.
Characteristics of HIV seronegative and seropositive women.
| HIV uninfected | HIV infected | p-Value | |
|---|---|---|---|
| Sample size (n) | 83 | 137 | |
| Age (yr) [media (Q1, Q3)] |
49.3 (43.9, 53.0) |
49.9 (46.9, 53.3) |
0.18 |
| Race (n) | |||
| White | 11 (13.25%) | 22 (16.06%) | 0.66 |
| Black | 60 (72.29%) | 91 (66.42%) | |
| Other | 12 (14.46%) | 24 (17.52%) | |
| Enrollment site (n) | |||
| Bronx NYC | 32 (38.55%) | 54 (39.42%) | 0.95 |
| San Francisco | 35 (42.17%) | 55 (40.15%) | |
| Chicago | 16 (19.28%) | 28 (20.44%) | |
| Menopausal status (n) | |||
| Premenopausal/early perimenopause | 34 (40.96%) | 46 (33.58%) | 0.27 |
| Late perimenopause/post-menopausal | 49 (59.04%) | 91 (66.42%) | |
| BMI (kg/m2) | |||
| <18.5 = thin | 2 (2.41%) | 2 (1.46%) | 0.42 |
| 18.5–24.9 = normal | 13 (15.66%) | 33 (24.09%) | |
| 25.0–29.9 = overweight | 24 (28.92%) | 41 (29.93%) | |
| ≥20.0 = obese | 44 (53.01%) | 61 (44.53%) | |
| Hepatitis C virus infection (n) | |||
| Negative | 62 (74.70%) | 91 (66.42%) | 0.087 |
| Resolved infection | |||
| (Ab & RNA negative) | 3 (3.61%) | 11 (8.03%) | |
| Ab & RNA unknown | 3 (3.61%) | 16 (11.68%) | |
| Active infection (RNA positive) | 15 (18.07%) | 19 (13.87%) | |
| Inflammatory cytokines (ng/mL) | |||
| TNFα [mean (SD)] | 1.29 (0.58) | 1.51 (0.88) | 0.10 |
| IL-6 [mean (SD)] | 0.04 (0.03) | 0.04 (0.03) | 0.11 |
| Bone turnover markers (ng/mL) | |||
| P1NP [mean (SD)] | 0.52 (0.28) | 0.60 (0.30) | 0.019 |
| CTX [mean (SD)] | 0.30 (0.21) | 0.35 (0.19) | 0.015 |
| Bone mineral density (g/cm2) | |||
| Weight bearing bones | |||
| Lumbar spine [mean (SD)] | 1.29 (0.21) | 1.20 (0.21) | 0.004 |
| Total hip [mean (SD)] | 1.08 (0.16) | 1.02 (0.15) | 0.009 |
| Femoral neck [mean (SD)] | 1.15 (0.18) | 1.09 (0.17) | 0.027 |
| Non-weight bearing bones | |||
| Distal radius [mean (SD)] | 0.84 (0.11) | 0.81 (0.14) | 0.27 |
| Ultradistal radius [mean (SD)] | 0.45 (0.07) | 0.42 (0.09) | 0.003 |
| Sclerostin (ng/mL) [mean (SD)] | 0.25 (0.14) | 0.27 (0.16) | 0.71 |
| CD4 count (cells/mL) [Median, Q1, Q3] |
NA | 566 (425, 762) |
NA |
| CD4 nadir (cells/mL) [Median, Q1, Q3] |
NA | 248 (152, 367) |
NA |
| HIV RNA viral load [Median, Q1, Q3] |
NA | 20 (20, 120) |
NA |
| Cumulative PI (years) [Median, Q1, Q3] |
NA | 3 (0, 9.5) |
NA |
| Cumulative NRTI (years) [Median, Q1, Q3] |
NA | 10 (3, 13.5) |
NA |
| Cumulative NNRTI (years) [Median, Q1, Q3] |
NA | 2.5 (0, 6) |
NA |
| Cumulative tenofovir disoproxil fumarate (TDF,years) [Median, Q1, Q3] |
NA | 2 (0, 6.5) |
NA |
| Cumulative abacavir (years) [Median, Q1, Q3] |
NA | 11 (3.5, 15.5) |
NA |
Abbreviations: BMI - body mass index, Ab - antibody, TNFα - tumor necrosis factor α, IL-6 - interleukin 6, P1NP - Procollagen type 1 N-terminal propeptide, CTX – C-telopeptide of type I collagen.
Bolded values indicate p<0.05.